SEC Form 4
Disc Medicine, Inc. (IRON) insider trading
In the 12 months to Oct 26, 2026, 6 IRON insiders reported open-market sales of $48.0M across 28 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $48.0M
- 28 filings · 6 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 25 of 28
- $29.1M of $48.0M sold (61%)
Who traded IRON, and when
- Sale
- Sale, pre-arranged (10b5-1)
IRON daily close from Oct 27, 2025 to Oct 26, 2026, between $55.74 and $94.11, last $77.66. 28 sale and 0 purchase filings by 6 insiders, marked at their filing dates. Kevin Bitterman, Director: sold $26.7M across 6 filings, first filed Dec 16, 2025, last Oct 21, 2026. John D. Quisel, Chief Executive Officer: sold $11.2M across 4 filings, first filed Dec 15, 2025, last Aug 18, 2026. Jonathan Yen-Wen Yu, Chief Operating Officer: sold $5.4M across 7 filings, first filed Nov 13, 2025, last Aug 26, 2026. William Jacob Savage, Chief Medical Officer: sold $2.1M across 3 filings, first filed Dec 16, 2025, last Apr 15, 2026. Rahul Khara, Chief Legal Officer: sold $1.7M across 5 filings, first filed Jan 5, 2026, last Aug 7, 2026. Jean M. Franchi, Chief Financial Officer: sold $948.8K across 3 filings, first filed Feb 19, 2026, last Apr 15, 2026.
Largest mark · tap a row for others
Kevin Bitterman · Director
Filing 1 of 2 within a week · $16,927,608 total
Sale $16,858,639
184,123 shares at $91.56 avg
Filed Dec 16, 2025 · traded Dec 12
Close on filing date $91.47
Kevin Bitterman · Director
Director
$26.7M soldJohn D. Quisel · Chief Executive Officer
Chief Executive Officer
$11.2M soldJonathan Yen-Wen Yu · Chief Operating Officer
Chief Operating Officer
$5.4M soldWilliam Jacob Savage · Chief Medical Officer
Chief Medical Officer
$2.1M soldRahul Khara · Chief Legal Officer
Chief Legal Officer
$1.7M soldJean M. Franchi · Chief Financial Officer
Chief Financial Officer
$948.8K soldOpen-market trades
28 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Kevin Bitterman | Director | $26.7M | — | 6 | 29% of sales | |
| John D. Quisel | Chief Executive Officer | $11.2M | — | 4 | 100% of sales | |
| Jonathan Yen-Wen Yu | Chief Operating Officer | $5.4M | — | 7 | 100% of sales | |
| William Jacob Savage | Chief Medical Officer | $2.1M | — | 3 | 100% of sales | |
| Rahul Khara | Chief Legal Officer | $1.7M | — | 5 | 100% of sales | |
| Jean M. Franchi | Chief Financial Officer | $948.8K | — | 3 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Kevin Bitterman Director | SalePre-arranged (10b5-1) | 41,825 | $80.13 | $3.4M | 296,277 | |
traded | Kevin Bitterman Director | Sale | 27,136 | $70.11 | $1.9M | 0 | |
traded | Kevin Bitterman Director | SalePre-arranged (10b5-1) | 1,689 | $79.96 | $135.1K | 312,230 | |
traded | Kevin Bitterman Director | SalePre-arranged (10b5-1) | 54,496 | $80.15 | $4.4M | 319,778 | |
traded | Jonathan Yen-Wen Yu Chief Operating Officer | SalePre-arranged (10b5-1) | 9,096 | $83.10 | $755.9K | 54,324 | |
traded | John D. Quisel Chief Executive Officer | SalePre-arranged (10b5-1) | 33,000 | $79.15 | $2.6M | 250,664 | |
traded | Jonathan Yen-Wen Yu Chief Operating Officer | SalePre-arranged (10b5-1) | 804 | $82.64 | $66.4K | 54,324 | |
traded | Rahul Khara Chief Legal Officer | SalePre-arranged (10b5-1) | 5,000 | $80.00 | $400.0K | 52,324 | |
traded | John D. Quisel Chief Executive Officer | SalePre-arranged (10b5-1) | 33,000 | $74.96 | $2.5M | 226,064 | |
traded | Jonathan Yen-Wen Yu Chief Operating Officer | SalePre-arranged (10b5-1) | 100 | $82.50 | $8.3K | 54,324 | |
traded | Jonathan Yen-Wen Yu Chief Operating Officer | SalePre-arranged (10b5-1) | 300 | $72.50 | $21.8K | 54,324 | |
traded | Rahul Khara Chief Legal Officer | SalePre-arranged (10b5-1) | 2,500 | $75.00 | $187.5K | 52,173 | |
traded | Jonathan Yen-Wen Yu Chief Operating Officer | SalePre-arranged (10b5-1) | 9,700 | $72.66 | $704.8K | 54,324 | |
traded | John D. Quisel Chief Executive Officer | SalePre-arranged (10b5-1) | 34,000 | $70.21 | $2.4M | 226,064 | |
traded | Rahul Khara Chief Legal Officer | SalePre-arranged (10b5-1) | 7,500 | $70.22 | $526.7K | 52,173 | |
traded | Jonathan Yen-Wen Yu Chief Operating Officer | SalePre-arranged (10b5-1) | 18,612 | $69.19 | $1.3M | 54,324 | |
traded | Jean M. Franchi Chief Financial Officer | SalePre-arranged (10b5-1) | 6,657 | $69.23 | $460.8K | 64,333 | |
traded | William Jacob Savage Chief Medical Officer | SalePre-arranged (10b5-1) | 5,731 | $66.38 | $380.4K | 79,480 | |
traded | William Jacob Savage Chief Medical Officer | SalePre-arranged (10b5-1) | 7,378 | $65.88 | $486.1K | 88,197 | |
traded | Jean M. Franchi Chief Financial Officer | SalePre-arranged (10b5-1) | 353 | $69.06 | $24.4K | 70,990 | |
traded | Jean M. Franchi Chief Financial Officer | SalePre-arranged (10b5-1) | 7,081 | $65.47 | $463.6K | 75,027 | |
traded | Rahul Khara Chief Legal Officer | SalePre-arranged (10b5-1) | 1,000 | $69.74 | $69.7K | 37,793 | |
traded | Rahul Khara Chief Legal Officer | SalePre-arranged (10b5-1) | 6,500 | $78.69 | $511.5K | 43,943 | |
traded | Kevin Bitterman Director | Sale | 754 | $91.47 | $69.0K | 14,013 | |
traded | Kevin Bitterman Director | Sale | 184,123 | $91.56 | $16.9M | Multiple accounts | |
traded | William Jacob Savage Chief Medical Officer | SalePre-arranged (10b5-1) | 13,093 | $91.22 | $1.2M | 76,002 | |
traded | John D. Quisel Chief Executive Officer | SalePre-arranged (10b5-1) | 40,000 | $93.05 | $3.7M | 205,072 | |
traded | Jonathan Yen-Wen Yu Chief Operating Officer | SalePre-arranged (10b5-1) | 30,000 | $84.70 | $2.5M | 48,595 |
GET /stocks/filings/vX/form-4?tickers=IRON&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"IRON"
],
"issuer_cik": "0001816736",
"owner_cik": "0001591747",
"accession_number": "0001591747-26-000009",
"form_type": "4",
"filing_date": "2026-10-21",
"period_of_report": "2026-10-19",
"issuer_name": "Disc Medicine, Inc.",
"issuer_trading_symbol": "IRON",
"owner_name": "Bitterman Kevin",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-21",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 266,
"transaction_price_per_share": 80.23,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 12991,
"transaction_value": 21341.18,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnote",
"footnotes": [
{
"id": "F1",
"description": "Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026."
},
{
"id": "F7",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
},
{
"id": "F5",
"description": "These shares are held by Atlas Venture Fund XII, L.P. (\"Atlas XII\"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. (\"Associates XII\"). Atlas Venture Associates XII, LLC (\"Associates XII LLC\") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any."
}
]
},
{
"tickers": [
"IRON"
],
"issuer_cik": "0001816736",
"owner_cik": "0001591747",
"accession_number": "0001591747-26-000009",
"form_type": "4",
"filing_date": "2026-10-21",
"period_of_report": "2026-10-19",
"issuer_name": "Disc Medicine, Inc.",
"issuer_trading_symbol": "IRON",
"owner_name": "Bitterman Kevin",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-19",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 4942,
"transaction_price_per_share": 79.97,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 307288,
"transaction_value": 395211.74,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnote",
"footnotes": [
{
"id": "F1",
"description": "Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.2476 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
},
{
"id": "F4",
"description": "These shares are held by Atlas Venture Opportunity Fund II, L.P. (\"Opportunity II\"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, L.P. (\"Associates II\"). Atlas Venture Associates Opportunity II, LLC (\"Associates II LLC\") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 41 records
- Option exercises29 records
- Tax withholding (sold to cover)6 records
- Grants and awards6 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Disc Medicine, Inc.'s CEO sold stock?
Yes. John D. Quisel (CEO) sold 140,000 shares ($11.2M) between Dec 2025 and Aug 2026, all under a pre-arranged 10b5-1 plan.
How current is IRON’s insider data?
These are IRON Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track IRON insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for IRON every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.